Clinical Trial Detail

NCT ID NCT00940316
Title Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Northwestern University
Indications

colorectal cancer

Therapies

Irinotecan

Erlotinib + Panitumumab

Age Groups: adult

No variant requirements are available.